Already have an account? log in
This article is FREE for you
Create a free account and join institutional investors, analysts and strategists from the world's largest banks
By submitting your email address you agree to receive communication by email
Flaming Butterflies
The crisis at Silicon Valley Bank managed to outcompete US payrolls for space above the digital fold
OR, subscribe now for unlimited access
By submitting your email address you agree to receive communication by email
By submitting your email address you agree to receive communication by email
Gosh, the comments from Goldman, Anderson and El Erian sound like the same reassuring chatter we heard from the street in late 2008 & even into early 2009.
SVB is not some obscure crypto player. Before we all chortle about VC players getting what they deserve, remember where many of the recent medical breakthroughs (such as Covid vaccines) came from.
Almost all modern medical and technological advances can be traced back decades to federal government (i.e., public, not private) funding.
Both government (funding for basic research) and private (commercial drug development) are required to bring new drugs to market. Research from NIH and academic labs identifies many possibilities for new pathways and therapies, but the vast majority will be dead-ends. VCs and industry are necessary to sift through the mountains of chaff to find the grains of wheat.
The failure rate for compounds moving from pre-clinical to phase 1 is about 90%, the failure rate from phase 1 to phase 2 is similar, and so on. Well less than one-thousandth of possible drugs identified at the pre-clinical stage ever make it to market, and only a small fraction of those are commercially and clinically successful. For those that are, the typical payback period, i.e. when the ROI turns positive, is several years.
Because the sifting process is so fantastically difficult and expensive, it requires rich economic incentives.
(Basis: a decade managing a biotech and pharma sleeve, focused on clinical stage “binary” names.)
JL – Thanks for the inside view. To some extent, the large pharma firms have outsourced much of their basic to VC-funded entities, which they look to buy once the probabilities of success look attractive, no?
I’ve read about VC-funded start-ups around Route 128 dropping projects, even ones they’ve sunk a lot of time and money into.
VC firms do not solely fund meal delivery and scooter rental start-ups.
Yes, big pharma now relies less on internal early stage drug development and more on buying de-risked drug programs.